Evidence map›Paper›PMID 30023671›Full record

ArticleACS omega2017

Quantification of Circulating Cancer Biomarkers via Sensitive Topographic Measurements on Single Binder Nanoarrays.

Elena Ambrosetti, Pamela Paoletti, Alessandro Bosco, Pietro Parisse, Denis Scaini, Elda Tagliabue, Ario de Marco, Loredana Casalis

Abstract read
In one paragraph

Article in ACS omega, 2017. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
8citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

8 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Article
  3. Article
  4. Article
  5. Computational Evolution Protocol for Peptide Design.Methods in molecular biology (Clifton, N.J.) · 2022
    Article
  6. Article
  7. Review
  8. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Elena AmbrosettiNanoInnovation Lab, Elettra-Sincrotone S.C.p.A., ss 14 km 163.5 in Area Science Park, 34149 Basovizza-Trieste, Italy.
Pamela PaolettiNanoInnovation Lab, Elettra-Sincrotone S.C.p.A., ss 14 km 163.5 in Area Science Park, 34149 Basovizza-Trieste, Italy.
Alessandro BoscoDepartment of Medical Biochemistry and Biophysics, Karolinska Institutet, Scheeles väg, 17177 Stockholm, Sweden.
Pietro ParisseNanoInnovation Lab, Elettra-Sincrotone S.C.p.A., ss 14 km 163.5 in Area Science Park, 34149 Basovizza-Trieste, Italy.
Denis ScainiNanoInnovation Lab, Elettra-Sincrotone S.C.p.A., ss 14 km 163.5 in Area Science Park, 34149 Basovizza-Trieste, Italy.
Elda TagliabueDepartment of Experimental Oncology and Molecular Medicine, Fondazione IRCCS-Istituto Nazionale dei Tumori, Via Amadeo 42, 20133 Milano, Italy.
Ario de MarcoCenter for Biomedical Sciences and Engineering, University of Nova Gorica, Dvorec Lanthieri, Glavni Trg 8, 5271 Vipava, Slovenia.
Loredana CasalisNanoInnovation Lab, Elettra-Sincrotone S.C.p.A., ss 14 km 163.5 in Area Science Park, 34149 Basovizza-Trieste, Italy.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Early detection of cancer plays a crucial role in disease prognosis. It requires the recognition and quantification of low amounts of specific molecular biomarkers, either free or transported inside nanovesicles, through the development of novel sensitive diagnostic technologies. In this context, we have developed a nanoarray platform for the noninvasive quantification of cancer biomarkers circulating in the bloodstream. The assay is based on molecular manipulation to create functional spots of surface-immobilized binders and differential topography measurements. It is label-free and requires just a single binder per antigen, and when it is implemented with fluorescence labeling/readout, it can be used for epitope mapping. As a benchmark, we focused on the plasma release of Her2 extracellular domain (ECD), a proposed biomarker for the progression of Her2-positive tumors and response to anticancer therapies. By employing robust, easily engineered camelid nanobodies as binders, we measured ECD-Her2 concentrations in the range of the actual clinical cutoff value for Her2-positive breast cancer. The specificity for Her2 detection was preserved when it was measured in parallel with other potential biomarkers, demonstrating a forthcoming implementation of this approach for multiplexing analysis. Prospectively, this nanorarray platform may be customized to allow for the detection of promising new classes of circulating biomarkers, such as exosomes and microvesicles.

Identifiers

PMID30023671
PMCPMC6044866

What OpenQuestion holds

Textmetadata
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.